David Nicholson

Responsible for developing over 25 new drug products in his career, David brings a wealth of drug hunting experience to Exscientia’s board. He has held a number of senior leadership positions over a 40-year career in research and development at Allergan, Bayer, Merck, Schering-Plough, and Organon. Dr. Nicholson brings a wealth of experience having previously championed the breakthrough anti-PD1 cancer drug Keytruda® (pembrolizumab) all the way from its earliest research and into development, heralding a revolution in cancer therapy.